von Hippel-Lindau disease: Clinical and molecular perspectives
- 1 January 2001
- book chapter
- Published by Elsevier in Advances in Cancer Research
- Vol. 82, 85-105
- https://doi.org/10.1016/s0065-230x(01)82003-0
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Risk of multisystem disease in isolated ocular angioma (haemangioblastoma)Journal of Medical Genetics, 2000
- Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activityOncogene, 1999
- Familial non-VHL non-papillary clear-cell renal cancerThe Lancet, 1997
- Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesisHuman Molecular Genetics, 1996
- Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.Journal of Medical Genetics, 1995
- Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotypeHuman Mutation, 1995
- Detailed mapping of germline deletions of the von Hippel—Lindau disease tumour suppressor geneHuman Molecular Genetics, 1994
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993
- Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma.Journal of Medical Genetics, 1990
- Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinomaNature, 1988